S1429 Efficacy of Guselkumab in Moderately to Severely Active Crohn’s Disease According to Induction Clinical Response Status: Week 48 Results from the GALAXI 2 & 3 Phase 3 Trials
Anita Afzali(University of Cincinnati Medical Center), Geert D’Haens(Amsterdam University Medical Centers), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Mary Ellen Frustaci(Johnson & Johnson (United States)), Dino Tarabar(Military Medical Academy), Julián Panés(Hospital Clínic de Barcelona), Rian Van Rampelbergh(Janssen (Belgium)), Remo Panaccione(University of Calgary), Zijiang Yang(Xi'an Jiaotong University), Natalie A. Terry(Janssen (United States)), Minhu Chen(Sun Yat-sen University), Douglas C. Wolf(Atlanta Gastroenterology Associates), Emese Mihály(Semmelweis University), David T. Rubin(University of California System), Leonardo Salese(Johnson & Johnson (United States))
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k